A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
This study has been completed.
Study NCT00851890
Information provided by AbbVie
First Received on February 24, 2009.
Last Updated on February 6, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
